In a placebo-controlled phase III trial, cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, did not improve progression-free survival in patients with recurrent GBM [54]. This evidence concerns the gene VEGFA and glioblastoma.